Tigecycline 50 mg/Vial Powder for Solution for Infusion (EU CTD Q4: 2020)

Product description

Tigecycline 50 mg/Vial Powder for Solution for Infusion Reference Product: Tygacil® / Pfizer
Description: Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunitand blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation ofamino acid residues into elongating peptide chains. In general, Tigecycline is considered bacteriostatic. Tigecycline is indicated in adults and in children from the age of eight years for the treatment of the following infections: Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections and Complicated intra-abdominal infections (cIAI). Tigecycline should be used only in situations where other alternative antibiotics are not suitable. 
Dossier Status: On-going / EU CTD ready to file: Q4 2020 
Stability Studies: Zone II / Zone IVb
Shelf life (Originator): Two (2) years 
Batch Sizes: 11,790 vials
Pack Sizes: BT x 10 vials
Read more

Specifications

Categories APIsAntibiotics; Finished Dosage FormsInjectables; Contract Services - Contract ServicesLyophilisation
Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Supplied from Greece

More products from ANFARM HELLAS S.A.

View all our products (30)

Products from other suppliers

Tigecycline 50 mg/Vial Powder for Solution for Infusion (EU CTD Q4: 2020)

Contact information

Address

Telephone

Website

View all contact information